Pfizer Agrees to $325 Million Settlement for Fraudulant Marketing of Neurontin

Pfizer Inc. and Warner-Lambert Co. LLC have agreed to pay $325 million in settlement of a lawsuit brought by a class of third-party payers. It was alleged that the drug Neurontin had been fraudulently marketed by Pfizer and Warner-Lambert. All of the claims brought by class members arising out of the sale and marketing of Neurontin will be resolved. The Plaintiffs’ motion for preliminary approval of the settlement came just more than a month after Pfizer agreed to settle the remaining claims for attorneys’ fees in Kaiser Foundation Health Plan Inc.’s suit against the drug manufacturer in the multidistrict litigation (MDL).
The class Plaintiffs, which include Harden Manufacturing Corp., Louisiana Blue Cross/Blue Shield and others, were ready to bring the litigation to an end. The members of the class Plaintiffs’ steering committee (PSC) wrote in a memorandum in support of the settlement:
This settlement, which provides significant and long-awaited benefits to class members, exceeds the standard for preliminary approval of a class action settlement.
The settlement came less than a month after Pfizer agreed to settle another suit in the MDL. Pfizer agreed in that settlement to pay Kaiser, a health maintenance organization, an undisclosed amount of attorneys’ fees. Since 2004, payers of Neurontin have accused the Defendants in several suits of fraudulently marketing the drug and causing them economic harm. Those suits were ultimately centralized before the United States District Court for the District of Massachusetts for MDL proceedings.
In the newly settled suit, class Plaintiffs alleged a fraudulent scheme to market and sell Neurontin for a variety of uses not approved by the U.S. Food and Drug Administration (FDA). The defendants sought to market the drug for several off-label uses in a variety of ways, including through false or misleading statements to physicians, according to the suit. The third-party payers involved in the action include insurance companies, health care benefit providers, union health and welfare plans and others. The class Plaintiffs have sought preliminary approval of the settlement and certification of the class for settlement purposes. They have asked for date for a final approval hearing.

Testosterone Replacement Therapy Litigation



On June 6, 2014, the United States Judicial Panel on Multidistrict Litigation established MDL No. 2545.

Lawyers for Plaintiffs, representing folks injured by Testosterone drugs, favored consolidation of all testosterone manufacturers into one MDL proceeding. The Defendants’ positions varied, with several Defendants, including AbbVie Inc. and Abbott Laboratories Inc. , Eli Lilly and Co. and Lilly USA LLC, and Endo Pharmaceuticals, supporting the establishment of an all-testosterone replacement therapy MDL in the Northern District of Illinois. Defendants Actavis, Inc., Auxilium Pharmaceuticals, Inc., Pfizer, Inc. and Pharmacia & Upjohn Co. all generally opposed the creation of an MDL consolidating all testosterone products and argued alternatively that the MDL should only include testosterone gel products.
” The Panel quoted the January 31, 2014, U.S. Food and Drug Administration (FDA) announcement that it is currently investigating the risk of stroke, heart attack, and death in men taking testosterone drugs approved by the FDA.